Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder.

Laffont CM, Gomeni R, Heidbreder C, Jones JP 3rd, Nasser AF.

J Clin Pharmacol. 2016 Jul;56(7):806-15. doi: 10.1002/jcph.665. Epub 2016 Mar 11.

PMID:
26479717
3.

Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.

Nasser AF, Greenwald MK, Vince B, Fudala PJ, Twumasi-Ankrah P, Liu Y, Jones JP 3rd, Heidbreder C.

J Clin Psychopharmacol. 2016 Feb;36(1):18-26. doi: 10.1097/JCP.0000000000000434.

4.
5.

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Ling W, Heidbreder C; RB-US-13-0001 Study Investigators.

Lancet. 2019 Feb 23;393(10173):778-790. doi: 10.1016/S0140-6736(18)32259-1. Epub 2019 Feb 18.

PMID:
30792007
6.

Pharmacokinetics of a Sustained Release Formulation of Buprenorphine After Intramuscular and Subcutaneous Administration to American Kestrels ( Falco sparverius ).

Guzman DS, Knych HK, Olsen GH, Paul-Murphy JR.

J Avian Med Surg. 2017 Jun;31(2):102-107. doi: 10.1647/2015-155.

PMID:
28644085
7.

Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone.

Laffont CM, Gomeni R, Zheng B, Heidbreder C, Fudala PJ, Nasser AF.

J Clin Pharmacol. 2015 Jan;55(1):93-103. doi: 10.1002/jcph.366. Epub 2014 Jul 23.

PMID:
25043337
8.

Evaluation of an injection depot formulation of buprenorphine: placebo comparison.

Sigmon SC, Wong CJ, Chausmer AL, Liebson IA, Bigelow GE.

Addiction. 2004 Nov;99(11):1439-49.

PMID:
15500597
9.
10.

Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices.

Greenwald M, Johanson CE, Bueller J, Chang Y, Moody DE, Kilbourn M, Koeppe R, Zubieta JK.

Biol Psychiatry. 2007 Jan 1;61(1):101-10. Epub 2006 Sep 1.

PMID:
16950210
11.

A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration.

Kalluri HV, Zhang H, Caritis SN, Venkataramanan R.

Br J Clin Pharmacol. 2017 Nov;83(11):2458-2473. doi: 10.1111/bcp.13368. Epub 2017 Aug 22.

12.

Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder.

Haasen C, Linden M, Tiberg F.

J Subst Abuse Treat. 2017 Jul;78:22-29. doi: 10.1016/j.jsat.2017.04.008. Epub 2017 Apr 14.

PMID:
28554599
13.
14.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
15.

Once-monthly subcutaneous buprenorphine (Sublocade) for opioid use disorder.

[No authors listed]

Med Lett Drugs Ther. 2018 Feb 26;60(1541):35-37. No abstract available.

PMID:
29485976
16.

Buprenorphine: new tricks with an old molecule for pain management.

Heit HA, Gourlay DL.

Clin J Pain. 2008 Feb;24(2):93-7. doi: 10.1097/AJP.0b013e31815ca2b4. Review. Erratum in: Clin J Pain. 2008 May;24(4):370.

PMID:
18209513
17.

Plasma concentrations of buprenorphine following a single subcutaneous administration of a sustained release formulation of buprenorphine in sheep.

Zullian C, Lema P, Lavoie M, Dodelet-Devillers A, Beaudry F, Vachon P.

Can J Vet Res. 2016 Jul;80(3):250-3.

18.

Advances in the delivery of buprenorphine for opioid dependence.

Rosenthal RN, Goradia VV.

Drug Des Devel Ther. 2017 Aug 28;11:2493-2505. doi: 10.2147/DDDT.S72543. eCollection 2017. Review.

19.

Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Greenwald MK, Comer SD, Fiellin DA.

Drug Alcohol Depend. 2014 Nov 1;144:1-11. doi: 10.1016/j.drugalcdep.2014.07.035. Epub 2014 Aug 19. Review.

20.

Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.

Kögel B, Christoph T, Strassburger W, Friderichs E.

Eur J Pain. 2005 Oct;9(5):599-611.

PMID:
16139189

Supplemental Content

Support Center